Autologous-allogeneic <i>versus</i> autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients under 60 years of age: a prospective, phase II study

Autologous-allogeneic <i>versus</i> autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients under 60 years of age: a prospective, phase II study

The role of autologous-allogeneic tandem stem cell transplantation (alloTSCT) followed by maintenance as upfront treatment for multiple myeloma is controversial. Between 2008 and 2014 a total of 217 multiple myeloma patients with a median age of 51 years were included by 20 German centers within an...

Full description

Bibliographic Details
Main Authors: Nicolaus Kröger, Gerald Wulf, Ute Hegenbart, Andreas Burchert, Matthias Stelljes, Nico Gagelmann, Arne Brecht, Martin Kaufmann, Lutz Müller, Arnold Ganser, Dominik Wolf, Wolfgang Bethge, Martin Bornhäuser, Michael Kiehl, Eva-Maria Wagner, Christoph Schmid, Hans Christian Reinhardt, Guido Kobbe, Hans Salwender, Thomas Heinicke, Martin Kropff, Marion Heinzelmann, Francis Ayuk, Lorenz Trümper, Andreas Neubauer, Andreas Völp, Evgeny Kluychnikov, Stefan Schönland, Christine Wolschke
Format: Article
Language:English
Published: Ferrata Storti Foundation 2023-11-01
Series:Haematologica
Online Access:https://haematologica.org/article/view/11335

Internet

https://haematologica.org/article/view/11335

Similar Items